Overview

A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C

Status:
Completed
Trial end date:
2019-05-28
Target enrollment:
Participant gender:
Summary
This is a study of experimental medication BMS-986263 in adult patients with advanced hepatic fibrosis (scar tissue in the liver caused by inflammation that is far on in progress) after the patient is cured of hepatitis C (an infection caused by a virus that attacks the liver and leads to inflammation).
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb